Promoting collaboration with international stakeholders in the HIV and other infectious diseases fields is a central theme in EuroVacc’s mission, in order to broaden the discovery program and advance the product and clinical development of the most promising vaccine candidates.
In collaboration with the HIV Vaccine Trial Network (HVTN), Division of AIDS/NIH, EuroVacc has co-sponsored a number of phase I trials, primarily for the evaluation of DNA and NYVAC combination with or without protein (see Clinical Studies) and several new trials are in the planning. Most of these trials are part of the Pox Protein Public Private Partnership (P5) clinical development plan with the goal to build on the RV144 success and evaluate potentially improved pox-protein vaccines to determine if they might provide significant public health benefit.
European HIV Vaccine Alliance (EHVA) is a large consortium funded by the European Union Horizon 2020 program. EHVA brings together 39 partners from 11 countries in Europe, 4 in Sub-Sahara Africa and the US. Its primary objectives are to develop and implement: 1) Discovery Platform with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses; 2) Immune Profiling Platform with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile; 3) Data Management/Integration/Down-Selection Platform, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines; 4) Clinical Trials Platform with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure.
EHVA is coordinated by the Institute National de la Santé et de la Recherche Médicale (INSERM) and the scientific leadership is carried out conjointly with the Lausanne University Hospital (CHUV). EuroVacc provides the scientific project management support to the program.
Dissecting the Immunological Interplay between Poverty Related Diseases and Helminth Infections: An African-European Research Initiative (IDEA) is a project funded by the European Union FP7 program with more than 20 institutes from Europe and Sub-Sahara Africa. IDEA focuses its efforts on four primary objectives: a) the worm-induced modulation of the functional and molecular profile of HIV-, TB- and malaria-specific immune responses, b) the impact by worm co-infections on measures of disease activity of PRDs, c) the immunologic markers of worm-, HIV-, TB- and malaria-specific immune responses associated with better control of pathogen replication and disease, and d) the modulation by worm co-infections of vaccine-induced immune responses.
IDEA is coordinated by the Lausanne University Hospital (CHUV). EuroVacc has provided the support in project management and has sponsored the HIV vaccine trial (EV06).
For more information, see also the European Commision website: http://cordis.europa.eu/project/rcn/94020_en.html